EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.
News|Articles|January 9, 2026
The top stories in glaucoma to enter the new year with
Author(s)Jordana Joy, Editor
New clinical data and trial updates closed out 2025.
Advertisement
Advertisement
Going into 2026, what do we now know about glaucoma that we didn’t a year ago? The last quarter of 2025 brought on new clinical data and trial updates for the leading cause of irreversible blindness. In case you missed it, here are the top stories that wrapped up last year.
Related to this article
Optometrists should know what is expected, what is concerning, and when to contact the surgeon.
The latest in drug and technology developments and updates from August 2026.
Host Hamza Shah, OD, MS, FAAO, is joined by Leonard Messner, OD, to discuss GLP-1s and idiopathic intracranial hypertension, inspired by Mitchell et al's paper, "The Effect of GLP-1RA Exenatide on Idiopathic Intracranial Hypertension: A Randomized Clinical Trial."
Catch up on the top stories in optometry during the week of August 24-28.
The agency assigned a PDUFA target action date of April 30, 2027.
Monica Jong, BOptom, PhD, FAAO, FBCLA, discussed the latest findings on Stellest lenses' effectiveness in myopia progression control and her advice for optometrists integrating the lenses into practice.
Maria Sampalis, OD, is an advocate for getting artificial intelligence to do tasks that provide more time to spend with patients, such as letter-writing.
Advertisement
Advertisement